January 9, 2017—Cancer and orphan drugs that command high prices increasingly dominate drug company pipelines, a new study shows.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)